ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Pediatric Pulmonology
Efficacy of lung surfactant combined with budesonide in improving bronchopulmonary dysplasia and growth of very low birth weight infants
Provisionally accepted
- Second Affiliated Hospital of Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: There is few treatments for bronchopulmonary dysplasia (BPD), and systemic glucocorticoid therapy has serious side effects. Methods: Low birth weight infants were classified randomly into control group administered with pulmonary surfactant (200mg/kg) and intervention group administered with pulmonary surfactant (200mg/kg) and budesonide suspension (0.25mg/kg) to explore the efficacy of combination of pulmonary surfactant and budesonide suspension is better than that of pulmonary surfactant alone. Results: The incidence of bronchopulmonary dysplasia was significantly lower in the intervention group (45%) compared to the control group (64%). Additionally, the duration of invasive ventilator use was significantly shorter in the intervention group (66.39±37.09 hours) than in the control group (82.05±54.55 hours); and the infants from the intervention group had a significantly shorter supplemental oxygen time, with the intervention group at 775.32±396.06 hours and the control group at 844.01 ±414.18 hours. Comparison of the basic conditions of the two groups of children showed no statistically significant differences in maternal medical history, gestational age, birth weight, sex, whether hormones were used prenatally, and delivery method (P>0.05). There was no difference in the incidence of complications, such as neonatal infection, intracranial hemorrhage, necrotizing enterocolitis, and retinopathy between the two groups. Conclusion: Combination of pulmonary surfactant with budesonide suspension can significantly decrease the incidence of bronchopulmonary dysplasia in very low birth weight infants, reduce the duration of invasive mechanical ventilation, and promote earlier weaning from oxygen supplement.
Keywords: Budesonide suspension, pulmonary surfactant, Clinical Trial, localapplication, Bronchopulmonary Dysplasia
Received: 16 Aug 2025; Accepted: 30 Oct 2025.
Copyright: © 2025 Zhang, Zhang, Liu, Li, Chi and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yunfeng Zhang, zhangyunf@jlu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.